Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogen commonly found in hospitals and other community settings. MRSA can cause several types of skin infections that can be life-threatening in some cases. Currently, around 4% of a particular pathogen, S. aureus, from Canadian hospitals have high-level resistance to the current antibiotic treatment. There is an urgent need to initiate efforts to develop a replacement antibiotic. Indolmycin, is a good option but extremely expensive.
This project aimed to develop a cheaper way to produce this medicine, to generate and test derivatives, and to understand potential modes of resistance. The long-term goal is to establish a start-up company for the development and licensing of the indolmycin-like antibiotics.